Heat shock protein-peptide complex in the treatment of glioblastoma

Alfred P. See, Gustavo Pradilla, Isaac Yang, Seunggu (Jude) Han, Andrew T. Parsa, Michael Lim

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Vaccination immunotherapies offer the promise of long-term tumor control, and preclinical trials have found promising results. Active immunotherapy uses the adaptive immune response to specifically kill tumor cells. Tumor-specific antigens are processed by antigen-presenting cells and recognized by specific effector lymphocytes. However, basic vaccination strategies with tumor lysates have been unsuccessful in inducing antiglioma immunity in clinical trials. Gliomas are known to modulate the activity of antigen-presenting cells to reduce antitumor immune activity. Recently, tumor-derived heat shock proteins have been found to more effectively activate the immune response. Widely expressed, heat shock proteins are thought to present protein peptide fragments in a format conducive to processing by antigen-presenting cells. As a part of the protein synthesis machinery, peptides complexed with heat shock proteins are effectively representative of antigens expressed by the cell; these peptides convey the specificity of this vaccination strategy. The heat shock protein-peptide vaccine is one of many promising immunotherapeutic strategies being evaluated in clinical trials. These can be broadly classified as active, passive and adoptive, each with advantages and disadvantages. Here, we compare and contrast heat shock protein-peptide vaccines with other immunotherapies and describe the outcomes of clinical trials to date.

Original languageEnglish (US)
Pages (from-to)721-731
Number of pages11
JournalExpert Review of Vaccines
Volume10
Issue number6
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Fingerprint

Glioblastoma
Heat-Shock Proteins
Antigen-Presenting Cells
Peptides
Vaccination
Subunit Vaccines
Clinical Trials
Immunotherapy
Neoplasms
Therapeutics
Active Immunotherapy
Peptide Fragments
Adaptive Immunity
Neoplasm Antigens
Glioma
Immunity
Proteins
Lymphocytes
Antigens

Keywords

  • antigen presentation
  • autologous vaccine
  • GBM
  • glioblastoma
  • heat shock protein
  • high-grade glioma
  • HSP
  • HSPPC-96
  • immunotherapy
  • oncophage
  • prophage
  • TAA
  • tumor-associated antigens
  • vitespen

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Heat shock protein-peptide complex in the treatment of glioblastoma. / See, Alfred P.; Pradilla, Gustavo; Yang, Isaac; Han, Seunggu (Jude); Parsa, Andrew T.; Lim, Michael.

In: Expert Review of Vaccines, Vol. 10, No. 6, 01.06.2011, p. 721-731.

Research output: Contribution to journalArticle

See, AP, Pradilla, G, Yang, I, Han, SJ, Parsa, AT & Lim, M 2011, 'Heat shock protein-peptide complex in the treatment of glioblastoma', Expert Review of Vaccines, vol. 10, no. 6, pp. 721-731. https://doi.org/10.1586/erv.11.49
See, Alfred P. ; Pradilla, Gustavo ; Yang, Isaac ; Han, Seunggu (Jude) ; Parsa, Andrew T. ; Lim, Michael. / Heat shock protein-peptide complex in the treatment of glioblastoma. In: Expert Review of Vaccines. 2011 ; Vol. 10, No. 6. pp. 721-731.
@article{f28a8b00ec3448b0925c1499bb3a3204,
title = "Heat shock protein-peptide complex in the treatment of glioblastoma",
abstract = "Vaccination immunotherapies offer the promise of long-term tumor control, and preclinical trials have found promising results. Active immunotherapy uses the adaptive immune response to specifically kill tumor cells. Tumor-specific antigens are processed by antigen-presenting cells and recognized by specific effector lymphocytes. However, basic vaccination strategies with tumor lysates have been unsuccessful in inducing antiglioma immunity in clinical trials. Gliomas are known to modulate the activity of antigen-presenting cells to reduce antitumor immune activity. Recently, tumor-derived heat shock proteins have been found to more effectively activate the immune response. Widely expressed, heat shock proteins are thought to present protein peptide fragments in a format conducive to processing by antigen-presenting cells. As a part of the protein synthesis machinery, peptides complexed with heat shock proteins are effectively representative of antigens expressed by the cell; these peptides convey the specificity of this vaccination strategy. The heat shock protein-peptide vaccine is one of many promising immunotherapeutic strategies being evaluated in clinical trials. These can be broadly classified as active, passive and adoptive, each with advantages and disadvantages. Here, we compare and contrast heat shock protein-peptide vaccines with other immunotherapies and describe the outcomes of clinical trials to date.",
keywords = "antigen presentation, autologous vaccine, GBM, glioblastoma, heat shock protein, high-grade glioma, HSP, HSPPC-96, immunotherapy, oncophage, prophage, TAA, tumor-associated antigens, vitespen",
author = "See, {Alfred P.} and Gustavo Pradilla and Isaac Yang and Han, {Seunggu (Jude)} and Parsa, {Andrew T.} and Michael Lim",
year = "2011",
month = "6",
day = "1",
doi = "10.1586/erv.11.49",
language = "English (US)",
volume = "10",
pages = "721--731",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Heat shock protein-peptide complex in the treatment of glioblastoma

AU - See, Alfred P.

AU - Pradilla, Gustavo

AU - Yang, Isaac

AU - Han, Seunggu (Jude)

AU - Parsa, Andrew T.

AU - Lim, Michael

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Vaccination immunotherapies offer the promise of long-term tumor control, and preclinical trials have found promising results. Active immunotherapy uses the adaptive immune response to specifically kill tumor cells. Tumor-specific antigens are processed by antigen-presenting cells and recognized by specific effector lymphocytes. However, basic vaccination strategies with tumor lysates have been unsuccessful in inducing antiglioma immunity in clinical trials. Gliomas are known to modulate the activity of antigen-presenting cells to reduce antitumor immune activity. Recently, tumor-derived heat shock proteins have been found to more effectively activate the immune response. Widely expressed, heat shock proteins are thought to present protein peptide fragments in a format conducive to processing by antigen-presenting cells. As a part of the protein synthesis machinery, peptides complexed with heat shock proteins are effectively representative of antigens expressed by the cell; these peptides convey the specificity of this vaccination strategy. The heat shock protein-peptide vaccine is one of many promising immunotherapeutic strategies being evaluated in clinical trials. These can be broadly classified as active, passive and adoptive, each with advantages and disadvantages. Here, we compare and contrast heat shock protein-peptide vaccines with other immunotherapies and describe the outcomes of clinical trials to date.

AB - Vaccination immunotherapies offer the promise of long-term tumor control, and preclinical trials have found promising results. Active immunotherapy uses the adaptive immune response to specifically kill tumor cells. Tumor-specific antigens are processed by antigen-presenting cells and recognized by specific effector lymphocytes. However, basic vaccination strategies with tumor lysates have been unsuccessful in inducing antiglioma immunity in clinical trials. Gliomas are known to modulate the activity of antigen-presenting cells to reduce antitumor immune activity. Recently, tumor-derived heat shock proteins have been found to more effectively activate the immune response. Widely expressed, heat shock proteins are thought to present protein peptide fragments in a format conducive to processing by antigen-presenting cells. As a part of the protein synthesis machinery, peptides complexed with heat shock proteins are effectively representative of antigens expressed by the cell; these peptides convey the specificity of this vaccination strategy. The heat shock protein-peptide vaccine is one of many promising immunotherapeutic strategies being evaluated in clinical trials. These can be broadly classified as active, passive and adoptive, each with advantages and disadvantages. Here, we compare and contrast heat shock protein-peptide vaccines with other immunotherapies and describe the outcomes of clinical trials to date.

KW - antigen presentation

KW - autologous vaccine

KW - GBM

KW - glioblastoma

KW - heat shock protein

KW - high-grade glioma

KW - HSP

KW - HSPPC-96

KW - immunotherapy

KW - oncophage

KW - prophage

KW - TAA

KW - tumor-associated antigens

KW - vitespen

UR - http://www.scopus.com/inward/record.url?scp=79959543340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959543340&partnerID=8YFLogxK

U2 - 10.1586/erv.11.49

DO - 10.1586/erv.11.49

M3 - Article

VL - 10

SP - 721

EP - 731

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 6

ER -